Locked nucleic acid: modality, diversity, and drug discovery

Area of Science:

• Oligonucleotide chemistry and RNA biology
• Drug discovery and pharmacology

Background:

• RNA-targeted therapeutics have advanced over 20 years through modified oligonucleotide chemistries and cellular assays.
• Locked nucleic acid (LNA) is a key technology, known for high binding affinity and potency.
• Advances in RNA biology offer new therapeutic targets.

Purpose of the Study:

• To outline new principles for drug discovery in RNA-targeted therapeutics.
• To exploit oligonucleotide diversity for identifying novel drug candidates.
• To understand how small structural differences impact pharmacological properties.

Main Methods:

• Review of advancements in oligonucleotide chemistry and RNA biology.
• Analysis of cellular assays for evaluating oligonucleotide properties in vivo.
• Exploitation of oligonucleotide diversity in drug discovery.

Main Results:

• Each oligonucleotide possesses unique properties influenced by subtle structural variations.
• Significant differences in pharmacological properties arise from small structural changes.
• A strategy for identifying rare molecules with unique pharmacological profiles is presented.

Conclusions:

• Oligonucleotide diversity is a critical factor in drug discovery for RNA-targeted therapeutics.
• New principles can leverage this diversity to find potent and effective drug candidates.
• Further research into structure-property relationships will advance the field.